<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00347269</url>
  </required_header>
  <id_info>
    <org_study_id>28630</org_study_id>
    <secondary_id>U01MH057858-05</secondary_id>
    <secondary_id>DSIR 83-ATAS</secondary_id>
    <nct_id>NCT00347269</nct_id>
  </id_info>
  <brief_title>Primary Care Intervention Strategy for Anxiety Disorders</brief_title>
  <official_title>Coordinated Anxiety Learning and Management (CALM): Improving Primary Care Anxiety Outcomes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Mental Health (NIMH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Washington</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will compare the effectiveness of an intervention strategy for the treatment of
      people with post traumatic stress disorder, generalized anxiety disorder, panic disorder, and
      social anxiety disorder in the primary care setting.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Anxiety disorders are highly prevalent, distressing, and disabling. Most patients with
      anxiety disorders who do receive mental health treatment receive it in primary care settings,
      where the quality of care is generally insufficient. This intervention is geared towards
      testing the clinical effectiveness of a care-manager assisted chronic disease management
      program for four common anxiety disorders (post-traumatic stress disorder, generalized
      anxiety disorder, panic disorder, and social anxiety disorder) in the primary care setting.
      This approach has been shown to be effective for the treatment of depression.

      Participants in this randomized, controlled trial will either be assigned to the control
      group: treatment-as-usual (TAU) from their primary care provider (PCP); or to the
      intervention group: CALM (Coordinated Anxiety Learning and Management). Intervention subjects
      will choose to receive CBT, medication, or both for the treatment of their anxiety. Those who
      choose CBT will receive it from a study-trained Anxiety Clinical Specialist (ACS) in their
      respective clinic. For those who choose medication, the ACS will facilitate the delivery of,
      and adherence to, anti-anxiety medication which will be prescribed by the participant's PCP.
      In this stepped-care design, subject progress will be formally re-evaluated at 8-12 week
      intervals. If treatment progress is not satisfactory, options include: additional or modified
      treatment with current modality, switching to the other treatment modality, or adding the
      other modality. When remission is attained, the ACS will follow-up with participants on a
      monthly basis to review progress and practice anxiety-reduction strategies. Treatment will
      continue for up to 12 months. Participants in both study arms will undergo formal baseline
      and outcome assessment interviews conducted at the 6, 12, and 18 month follow-up time-points.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2006</start_date>
  <completion_date type="Actual">October 2009</completion_date>
  <primary_completion_date type="Actual">October 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>BSI-12 (Anxiety and Somatization Subscales)</measure>
    <time_frame>Measured at Month 18</time_frame>
    <description>12 items from the Brief Symptom Inventory that measure anxiety and anxiety0related physical symptoms</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Functioning Outcomes as Measured by 3-item Sheehan Disability Scales and SF-12 and Disorder-specific Severity Scales as Measured by the ASI, PDSS-SR, GADS (Modified), SPIN, PCL-C, and the PHQ-9</measure>
    <time_frame>Measured at Month 18</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1004</enrollment>
  <condition>Post-traumatic Stress Disorder</condition>
  <condition>Generalized Anxiety Disorder</condition>
  <condition>Panic Disorder</condition>
  <condition>Social Anxiety Disorder</condition>
  <arm_group>
    <arm_group_label>CALM Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participant choice of:
Cognitive Behavioral Therapy (CBT) Psychotropic (anti-anxiety) medication optimization</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment as Usual (TAU)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants assigned to TAU with their primary care provider (PCP)</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Cognitive-behavioral therapy</intervention_name>
    <description>Participants in CALM will choose to receive CBT, medication, or both for the treatment of their anxiety. CBT includes computer-assisted CBT with an anxiety clinical specialist.</description>
    <arm_group_label>CALM Intervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Psychotropic medication optimization</intervention_name>
    <description>For those participants in CALM who choose medication, the ACS will facilitate the delivery of, and adherence to, anti-anxiety medication which will be prescribed by the participants' PCP.</description>
    <arm_group_label>CALM Intervention</arm_group_label>
    <other_name>SSRI, SNRI, Benzodiazepine,</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Treatment as Usual</intervention_name>
    <description>Participants in the control group will receive standard treatment from their PCP.</description>
    <arm_group_label>Treatment as Usual (TAU)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  MINI diagnosed Anxiety Disorder (PTSD, GAD, SAD, PD)

          -  Speak English or Spanish (English only at UAMS site)

        Exclusion Criteria:

          -  Diagnosis of Bipolar 1

          -  Drug and alcohol dependence; or abuse of any substance other than marijuana and
             alcohol

          -  Acute suicidality or homicidality

        Eligible subjects must be current patients at one of the participating primary care clinics
        which include:

        University of Washington:

          -  Harborview's Adult Medicine Clinic

          -  Harborview's Family Medicine Clinic

          -  UWMC's General Internal Medicine Clinic at Roosevelt Clinic

          -  PSNHC's 45th Street Clinic

          -  Country Doctor Community Clinic

          -  Carolyn Downs Family Medical Center

        UCLA:

          -  Desert Medical Group, Palm Springs CA

          -  High Desert Medical Group, Lancaster, CA

        UCSD:

          -  Kaiser Permanente, Bonita Medical Offices

          -  Kaiser Permanente, Otay Mesa Outpatient Medical Center

          -  UCSD Medical Center, Scripps Ranch Medical Office

          -  UCSD Medical Center, Fourth and Lewis Medical Office

          -  UCSD Medical Center, Perlman Ambulatory Care Center

          -  Sharp Rees-Stealy Medical Group, El Cajon

          -  Sharp Rees-Stealy Medical Group, Mira Mesa

        UAMS:

          -  UAMS UPMG

          -  Little Rock Diagnostic Clinic

          -  St. Vincent's Family Clinic South
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter P. Roy-Byrne, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Washington</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Cathy D. Sherbourne, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>RAND Corporation, Santa Monica, CA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michelle G. Craske, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Los Angeles</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Greer Sullivan, MD, MSPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Arkansas for Medical Sciences, Little Rock, AR</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Murray B. Stein, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Diego, San Diego, CA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kristin Bumgardner, BS</last_name>
    <role>Study Director</role>
    <affiliation>University of Washington</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Arkansas for Medical Sciences</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037-0603</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095-1563</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Lang AJ, Wilkins K, Roy-Byrne PP, Golinelli D, Chavira D, Sherbourne C, Rose RD, Bystritsky A, Sullivan G, Craske MG, Stein MB. Abbreviated PTSD Checklist (PCL) as a guide to clinical response. Gen Hosp Psychiatry. 2012 Jul-Aug;34(4):332-8. doi: 10.1016/j.genhosppsych.2012.02.003. Epub 2012 Mar 27.</citation>
    <PMID>22460001</PMID>
  </reference>
  <reference>
    <citation>Craske MG, Roy-Byrne PP, Stein MB, Sullivan G, Sherbourne C, Bystritsky A. Treatment for anxiety disorders: Efficacy to effectiveness to implementation. Behav Res Ther. 2009 Nov;47(11):931-7. doi: 10.1016/j.brat.2009.07.012. Epub 2009 Jul 14. Review.</citation>
    <PMID>19632667</PMID>
  </reference>
  <reference>
    <citation>Roy-Byrne P, Veitengruber JP, Bystritsky A, Edlund MJ, Sullivan G, Craske MG, Welch SS, Rose R, Stein MB. Brief intervention for anxiety in primary care patients. J Am Board Fam Med. 2009 Mar-Apr;22(2):175-86. doi: 10.3122/jabfm.2009.02.080078.</citation>
    <PMID>19264941</PMID>
  </reference>
  <reference>
    <citation>Campbell-Sills L, Norman SB, Craske MG, Sullivan G, Lang AJ, Chavira DA, Bystritsky A, Sherbourne C, Roy-Byrne P, Stein MB. Validation of a brief measure of anxiety-related severity and impairment: the Overall Anxiety Severity and Impairment Scale (OASIS). J Affect Disord. 2009 Jan;112(1-3):92-101. doi: 10.1016/j.jad.2008.03.014. Epub 2008 May 16.</citation>
    <PMID>18486238</PMID>
  </reference>
  <reference>
    <citation>Sullivan G, Craske MG, Sherbourne C, Edlund MJ, Rose RD, Golinelli D, Chavira DA, Bystritsky A, Stein MB, Roy-Byrne PP. Design of the Coordinated Anxiety Learning and Management (CALM) study: innovations in collaborative care for anxiety disorders. Gen Hosp Psychiatry. 2007 Sep-Oct;29(5):379-87.</citation>
    <PMID>17888803</PMID>
  </reference>
  <results_reference>
    <citation>Brown LA, Krull JL, Roy-Byrne P, Sherbourne CD, Stein MB, Sullivan G, Rose RD, Bystritsky A, Craske MG. An examination of the bidirectional relationship between functioning and symptom levels in patients with anxiety disorders in the CALM study. Psychol Med. 2015 Feb;45(3):647-61. doi: 10.1017/S0033291714002062. Epub 2014 Oct 2.</citation>
    <PMID>25272965</PMID>
  </results_reference>
  <results_reference>
    <citation>Brown LA, Wiley JF, Wolitzky-Taylor K, Roy-Byrne P, Sherbourne C, Stein MB, Sullivan G, Rose RD, Bystritsky A, Craske MG. Changes in self-efficacy and outcome expectancy as predictors of anxiety outcomes from the CALM study. Depress Anxiety. 2014 Aug;31(8):678-89. doi: 10.1002/da.22256. Epub 2014 Mar 11.</citation>
    <PMID>24619599</PMID>
  </results_reference>
  <results_reference>
    <citation>Chavira DA, Golinelli D, Sherbourne C, Stein MB, Sullivan G, Bystritsky A, Rose RD, Lang AJ, Campbell-Sills L, Welch S, Bumgardner K, Glenn D, Barrios V, Roy-Byrne P, Craske M. Treatment engagement and response to CBT among Latinos with anxiety disorders in primary care. J Consult Clin Psychol. 2014 Jun;82(3):392-403. doi: 10.1037/a0036365. Epub 2014 Mar 24.</citation>
    <PMID>24660674</PMID>
  </results_reference>
  <results_reference>
    <citation>Dour HJ, Wiley JF, Roy-Byrne P, Stein MB, Sullivan G, Sherbourne CD, Bystritsky A, Rose RD, Craske MG. Perceived social support mediates anxiety and depressive symptom changes following primary care intervention. Depress Anxiety. 2014 May;31(5):436-42. doi: 10.1002/da.22216. Epub 2013 Dec 12.</citation>
    <PMID>24338947</PMID>
  </results_reference>
  <results_reference>
    <citation>Joesch JM, Golinelli D, Sherbourne CD, Sullivan G, Stein MB, Craske MG, Roy-Byrne PP. Trajectories of change in anxiety severity and impairment during and after treatment with evidence-based treatment for multiple anxiety disorders in primary care. Depress Anxiety. 2013 Nov;30(11):1099-106. doi: 10.1002/da.22149. Epub 2013 Jun 25.</citation>
    <PMID>23801589</PMID>
  </results_reference>
  <results_reference>
    <citation>Campbell-Sills L, Stein MB, Sherbourne CD, Craske MG, Sullivan G, Golinelli D, Lang AJ, Chavira DA, Bystritsky A, Rose RD, Welch SS, Kallenberg GA, Roy-Byrne P. Effects of medical comorbidity on anxiety treatment outcomes in primary care. Psychosom Med. 2013 Oct;75(8):713-20. doi: 10.1097/PSY.0b013e31829def54. Epub 2013 Jul 25.</citation>
    <PMID>23886736</PMID>
  </results_reference>
  <results_reference>
    <citation>Roy-Byrne P, Sullivan MD, Sherbourne CD, Golinelli D, Craske MG, Sullivan G, Stein MB. Effects of pain and prescription opioid use on outcomes in a collaborative care intervention for anxiety. Clin J Pain. 2013 Sep;29(9):800-6. doi: 10.1097/AJP.0b013e318278d475.</citation>
    <PMID>23370069</PMID>
  </results_reference>
  <results_reference>
    <citation>Bomyea J, Lang AJ, Craske MG, Chavira D, Sherbourne CD, Rose RD, Golinelli D, Campbell-Sills L, Welch SS, Sullivan G, Bystritsky A, Roy-Byrne P, Stein MB. Suicidal ideation and risk factors in primary care patients with anxiety disorders. Psychiatry Res. 2013 Aug 30;209(1):60-5. doi: 10.1016/j.psychres.2013.03.017. Epub 2013 Apr 19.</citation>
    <PMID>23608160</PMID>
  </results_reference>
  <results_reference>
    <citation>Glenn D, Golinelli D, Rose RD, Roy-Byrne P, Stein MB, Sullivan G, Bystritksy A, Sherbourne C, Craske MG. Who gets the most out of cognitive behavioral therapy for anxiety disorders? The role of treatment dose and patient engagement. J Consult Clin Psychol. 2013 Aug;81(4):639-649. doi: 10.1037/a0033403. Epub 2013 Jun 10.</citation>
    <PMID>23750465</PMID>
  </results_reference>
  <results_reference>
    <citation>Wetherell JL, Petkus AJ, Thorp SR, Stein MB, Chavira DA, Campbell-Sills L, Craske MG, Sherbourne C, Bystritsky A, Sullivan G, Roy-Byrne P. Age differences in treatment response to a collaborative care intervention for anxiety disorders. Br J Psychiatry. 2013 Jul;203(1):65-72. doi: 10.1192/bjp.bp.112.118547. Epub 2013 Apr 11.</citation>
    <PMID>23580378</PMID>
  </results_reference>
  <results_reference>
    <citation>Bomyea J, Lang AJ, Golinelli D, Craske MG, Chavira DA, Sherbourne CD, Rose RD, Campbell-Sills L, Welch SS, Sullivan G, Bystritsky A, Roy-Byrne P, Stein MB. Trauma Exposure in Anxious Primary Care Patients. J Psychopathol Behav Assess. 2013 Jun 1;35(2):254-263.</citation>
    <PMID>23729989</PMID>
  </results_reference>
  <results_reference>
    <citation>Niles AN, Sherbourne CD, Roy-Byrne PP, Stein MB, Sullivan G, Bystritsky A, Craske MG. Anxiety treatment improves physical functioning with oblique scoring of the SF-12 short form health survey. Gen Hosp Psychiatry. 2013 May-Jun;35(3):291-6. doi: 10.1016/j.genhosppsych.2012.12.004. Epub 2013 Jan 16.</citation>
    <PMID>23332608</PMID>
  </results_reference>
  <results_reference>
    <citation>Hunt J, Sullivan G, Chavira DA, Stein MB, Craske MG, Golinelli D, Roy-Byrne PP, Sherbourne CD. Race and beliefs about mental health treatment among anxious primary care patients. J Nerv Ment Dis. 2013 Mar;201(3):188-95. doi: 10.1097/NMD.0b013e3182845ad8.</citation>
    <PMID>23407203</PMID>
  </results_reference>
  <results_reference>
    <citation>Sullivan G, Sherbourne C, Chavira DA, Craske MG, Gollineli D, Han X, Rose RD, Bystritsky A, Stein MB, Roy-Byrne P. Does a quality improvement intervention for anxiety result in differential outcomes for lower-income patients? Am J Psychiatry. 2013 Feb;170(2):218-25. doi: 10.1176/appi.ajp.2012.12030375.</citation>
    <PMID>23377641</PMID>
  </results_reference>
  <results_reference>
    <citation>Brown LA, Craske MG, Glenn DE, Stein MB, Sullivan G, Sherbourne C, Bystritsky A, Welch SS, Campbell-Sills L, Lang A, Roy-Byrne P, Rose RD. CBT competence in novice therapists improves anxiety outcomes. Depress Anxiety. 2013 Feb;30(2):97-115. doi: 10.1002/da.22027. Epub 2012 Dec 5.</citation>
    <PMID>23225338</PMID>
  </results_reference>
  <results_reference>
    <citation>Zbozinek TD, Rose RD, Wolitzky-Taylor KB, Sherbourne C, Sullivan G, Stein MB, Roy-Byrne PP, Craske MG. Diagnostic overlap of generalized anxiety disorder and major depressive disorder in a primary care sample. Depress Anxiety. 2012 Dec;29(12):1065-71. doi: 10.1002/da.22026. Epub 2012 Nov 26.</citation>
    <PMID>23184657</PMID>
  </results_reference>
  <results_reference>
    <citation>Campbell-Sills L, Sherbourne CD, Roy-Byrne P, Craske MG, Sullivan G, Bystritsky A, Lang AJ, Chavira DA, Rose RD, Shaw Welch S, Stein MB. Effects of co-occurring depression on treatment for anxiety disorders: analysis of outcomes from a large primary care effectiveness trial. J Clin Psychiatry. 2012 Dec;73(12):1509-16. doi: 10.4088/JCP.12m07955.</citation>
    <PMID>23290323</PMID>
  </results_reference>
  <results_reference>
    <citation>Joesch JM, Sherbourne CD, Sullivan G, Stein MB, Craske MG, Roy-Byrne P. Incremental benefits and cost of coordinated anxiety learning and management for anxiety treatment in primary care. Psychol Med. 2012 Sep;42(9):1937-48. doi: 10.1017/S0033291711002893. Epub 2011 Dec 13.</citation>
    <PMID>22152230</PMID>
  </results_reference>
  <results_reference>
    <citation>Bystritsky A, Hovav S, Sherbourne C, Stein MB, Rose RD, Campbell-Sills L, Golinelli D, Sullivan G, Craske MG, Roy-Byrne PP. Use of complementary and alternative medicine in a large sample of anxiety patients. Psychosomatics. 2012 May-Jun;53(3):266-72. doi: 10.1016/j.psym.2011.11.009. Epub 2012 Feb 1.</citation>
    <PMID>22304968</PMID>
  </results_reference>
  <results_reference>
    <citation>Curran GM, Sullivan G, Mendel P, Craske MG, Sherbourne CD, Stein MB, McDaniel A, Roy-Byrne P. Implementation of the CALM intervention for anxiety disorders: a qualitative study. Implement Sci. 2012 Mar 9;7:1-11. doi: 10.1186/1748-5908-7-14.</citation>
    <PMID>22404963</PMID>
  </results_reference>
  <results_reference>
    <citation>Rose RD, Lang AJ, Welch SS, Campbell-Sills L, Chavira DA, Sullivan G, Sherbourne C, Bystritsky A, Stein MB, Roy-Byrne PP, Craske MG. Training primary care staff to deliver a computer-assisted cognitive-behavioral therapy program for anxiety disorders. Gen Hosp Psychiatry. 2011 Jul-Aug;33(4):336-42. doi: 10.1016/j.genhosppsych.2011.04.011. Epub 2011 Jun 8.</citation>
    <PMID>21762829</PMID>
  </results_reference>
  <results_reference>
    <citation>Stein MB, Roy-Byrne PP, Craske MG, Campbell-Sills L, Lang AJ, Golinelli D, Rose RD, Bystritsky A, Sullivan G, Sherbourne CD. Quality of and patient satisfaction with primary health care for anxiety disorders. J Clin Psychiatry. 2011 Jul;72(7):970-6. doi: 10.4088/JCP.09m05626blu. Epub 2011 Feb 22.</citation>
    <PMID>21367351</PMID>
  </results_reference>
  <results_reference>
    <citation>Craske MG, Stein MB, Sullivan G, Sherbourne C, Bystritsky A, Rose RD, Lang AJ, Welch S, Campbell-Sills L, Golinelli D, Roy-Byrne P. Disorder-specific impact of coordinated anxiety learning and management treatment for anxiety disorders in primary care. Arch Gen Psychiatry. 2011 Apr;68(4):378-88. doi: 10.1001/archgenpsychiatry.2011.25.</citation>
    <PMID>21464362</PMID>
  </results_reference>
  <results_reference>
    <citation>Sherbourne CD, Sullivan G, Craske MG, Roy-Byrne P, Golinelli D, Rose RD, Chavira DA, Bystritsky A, Stein MB. Functioning and disability levels in primary care out-patients with one or more anxiety disorders. Psychol Med. 2010 Dec;40(12):2059-68. doi: 10.1017/S0033291710000176. Epub 2010 Feb 11.</citation>
    <PMID>20146834</PMID>
  </results_reference>
  <results_reference>
    <citation>Roy-Byrne P, Craske MG, Sullivan G, Rose RD, Edlund MJ, Lang AJ, Bystritsky A, Welch SS, Chavira DA, Golinelli D, Campbell-Sills L, Sherbourne CD, Stein MB. Delivery of evidence-based treatment for multiple anxiety disorders in primary care: a randomized controlled trial. JAMA. 2010 May 19;303(19):1921-8. doi: 10.1001/jama.2010.608.</citation>
    <PMID>20483968</PMID>
  </results_reference>
  <results_reference>
    <citation>Chavira DA, Stein MB, Golinelli D, Sherbourne CD, Craske MG, Sullivan G, Bystritsky A, Roy-Byrne PP. Predictors of clinical improvement in a randomized effectiveness trial for primary care patients with panic disorder. J Nerv Ment Dis. 2009 Oct;197(10):715-21. doi: 10.1097/NMD.0b013e3181b97d4d.</citation>
    <PMID>19829198</PMID>
  </results_reference>
  <results_reference>
    <citation>Craske MG, Rose RD, Lang A, Welch SS, Campbell-Sills L, Sullivan G, Sherbourne C, Bystritsky A, Stein MB, Roy-Byrne PP. Computer-assisted delivery of cognitive behavioral therapy for anxiety disorders in primary-care settings. Depress Anxiety. 2009;26(3):235-42. doi: 10.1002/da.20542.</citation>
    <PMID>19212970</PMID>
  </results_reference>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 30, 2006</study_first_submitted>
  <study_first_submitted_qc>June 30, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 4, 2006</study_first_posted>
  <results_first_submitted>April 8, 2017</results_first_submitted>
  <results_first_submitted_qc>April 8, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">May 19, 2017</results_first_posted>
  <last_update_submitted>April 8, 2017</last_update_submitted>
  <last_update_submitted_qc>April 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Washington</investigator_affiliation>
    <investigator_full_name>Peter Roy-Byrne</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Anxiety Disorders</keyword>
  <keyword>Post-traumatic Stress Disorder</keyword>
  <keyword>Generalized Anxiety Disorder</keyword>
  <keyword>Panic Disorder</keyword>
  <keyword>Social Anxiety Disorder</keyword>
  <keyword>Stress</keyword>
  <keyword>Stress Disorders, Traumatic</keyword>
  <keyword>Stress Disorders, Post-Traumatic</keyword>
  <keyword>Mental Health Disorders</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Anxiety Disorders</mesh_term>
    <mesh_term>Stress Disorders, Traumatic</mesh_term>
    <mesh_term>Stress Disorders, Post-Traumatic</mesh_term>
    <mesh_term>Panic Disorder</mesh_term>
    <mesh_term>Phobia, Social</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psychotropic Drugs</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Limited access datasets are available through the National Database for Clinical Trials Related to Mental Illness (NDCT), part of the NIMH Data Archive: https://data-archive.nimh.nih.gov/ndct/.</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>CALM Intervention</title>
          <description>Participants assigned to coordinated anxiety learning and management (CALM)--
CALM consists of: patient choice of Cognitive Behavioral Therapy (CBT), psychotropic (anti-anxiety) medication optimization or both.
Optimization: 8 weeks of an evidence based anxiety medication at appropriate dose
Cognitive-behavioral therapy: Participants in CALM will choose to receive CBT, medication, or both for the treatment of their anxiety. CBT includes computer-assisted CBT with an anxiety clinical specialist.
Psychotropic medication optimization: For those participants in CALM who choose medication, the ACS will facilitate the delivery of, and adherence to, anti-anxiety medication which will be prescribed by the participants' PCP.</description>
        </group>
        <group group_id="P2">
          <title>Treatment as Usual (TAU)</title>
          <description>Participants assigned to TAU with their primary care provider (PCP)
Treatment as Usual: Participants in the control group will receive standard treatment from their PCP.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="503"/>
                <participants group_id="P2" count="501"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="409"/>
                <participants group_id="P2" count="395"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="94"/>
                <participants group_id="P2" count="106"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="74"/>
                <participants group_id="P2" count="65"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="38"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>CALM Intervention</title>
          <description>Participants assigned to coordinated anxiety learning and management (CALM)--
CALM consists of: patient choice of Cognitive Behavioral Therapy (CBT), psychotropic (anti-anxiety) medication optimization or both.
Optimization: 8 weeks of an evidence based anxiety medication at appropriate dose
Cognitive-behavioral therapy: Participants in CALM will choose to receive CBT, medication, or both for the treatment of their anxiety. CBT includes computer-assisted CBT with an anxiety clinical specialist.
Psychotropic medication optimization: For those participants in CALM who choose medication, the ACS will facilitate the delivery of, and adherence to, anti-anxiety medication which will be prescribed by the participants' PCP.</description>
        </group>
        <group group_id="B2">
          <title>Treatment as Usual (TAU)</title>
          <description>Participants assigned to TAU with their primary care provider (PCP)
Treatment as Usual: Participants in the control group will receive standard treatment from their PCP.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="503"/>
            <count group_id="B2" value="501"/>
            <count group_id="B3" value="1004"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43.3" spread="13.2"/>
                    <measurement group_id="B2" value="43.7" spread="13.7"/>
                    <measurement group_id="B3" value="43.4" spread="13.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="359"/>
                    <measurement group_id="B2" value="355"/>
                    <measurement group_id="B3" value="714"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="144"/>
                    <measurement group_id="B2" value="146"/>
                    <measurement group_id="B3" value="290"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="104"/>
                    <measurement group_id="B2" value="92"/>
                    <measurement group_id="B3" value="196"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="399"/>
                    <measurement group_id="B2" value="409"/>
                    <measurement group_id="B3" value="808"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="57"/>
                    <measurement group_id="B3" value="97"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="333"/>
                    <measurement group_id="B2" value="331"/>
                    <measurement group_id="B3" value="664"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="72"/>
                    <measurement group_id="B2" value="61"/>
                    <measurement group_id="B3" value="133"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="503"/>
                    <measurement group_id="B2" value="501"/>
                    <measurement group_id="B3" value="1004"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>BSI-12 (Anxiety and Somatization Subscales)</title>
        <description>12 items from the Brief Symptom Inventory that measure anxiety and anxiety0related physical symptoms</description>
        <time_frame>Measured at Month 18</time_frame>
        <group_list>
          <group group_id="O1">
            <title>CALM Intervention</title>
            <description>Participants assigned to coordinated anxiety learning and management (CALM)--
CALM consists of: patient choice of Cognitive Behavioral Therapy (CBT), psychotropic (anti-anxiety) medication optimization or both.
Optimization: 8 weeks of an evidence based anxiety medication at appropriate dose
Cognitive-behavioral therapy: Participants in CALM will choose to receive CBT, medication, or both for the treatment of their anxiety. CBT includes computer-assisted CBT with an anxiety clinical specialist.
Psychotropic medication optimization: For those participants in CALM who choose medication, the ACS will facilitate the delivery of, and adherence to, anti-anxiety medication which will be prescribed by the participants' PCP.</description>
          </group>
          <group group_id="O2">
            <title>Treatment as Usual (TAU)</title>
            <description>Participants assigned to TAU with their primary care provider (PCP)
Treatment as Usual: Participants in the control group will receive standard treatment from their PCP.</description>
          </group>
        </group_list>
        <measure>
          <title>BSI-12 (Anxiety and Somatization Subscales)</title>
          <description>12 items from the Brief Symptom Inventory that measure anxiety and anxiety0related physical symptoms</description>
          <units>number of responders</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="503"/>
                <count group_id="O2" value="501"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="325"/>
                    <measurement group_id="O2" value="258"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Functioning Outcomes as Measured by 3-item Sheehan Disability Scales and SF-12 and Disorder-specific Severity Scales as Measured by the ASI, PDSS-SR, GADS (Modified), SPIN, PCL-C, and the PHQ-9</title>
        <time_frame>Measured at Month 18</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>18 months</time_frame>
      <desc>As all treatments were part of standard care, both CBT and psychotropic medications routinely employed in clinical settings, no specific AE assessments were performed as would be done in clinical drug trials.</desc>
      <group_list>
        <group group_id="E1">
          <title>CALM Intervention</title>
          <description>Participants assigned to coordinated anxiety learning and management (CALM)--
CALM consists of: patient choice of Cognitive Behavioral Therapy (CBT), psychotropic (anti-anxiety) medication optimization or both.
Optimization: 8 weeks of an evidence based anxiety medication at appropriate dose
Cognitive-behavioral therapy: Participants in CALM will choose to receive CBT, medication, or both for the treatment of their anxiety. CBT includes computer-assisted CBT with an anxiety clinical specialist.
Psychotropic medication optimization: For those participants in CALM who choose medication, the ACS will facilitate the delivery of, and adherence to, anti-anxiety medication which will be prescribed by the participants' PCP.</description>
        </group>
        <group group_id="E2">
          <title>Treatment as Usual (TAU)</title>
          <description>Participants assigned to TAU with their primary care provider (PCP)
Treatment as Usual: Participants in the control group will receive standard treatment from their PCP.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="503"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="503"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="501"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="503"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="501"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Peter Roy-Byrne MD Professor of Psychiatry</name_or_title>
      <organization>University of Washington</organization>
      <phone>206-313-8504</phone>
      <email>roybyrne@u.washington.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

